Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax PharmaBOM:540359 +1.99%39 Days Payable is 402.31 as of Mar. 2026, which is 72% above its 10-year median of 233.36. GuruFocus rates BOM:540359 with a GF Score™ of 39/100 and a GF Value™ of ₹25.56 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 925 Drug Manufacturers companies, Parmax Pharma ranks better than 93.41% on this metric.
The historical rank and industry rank for Parmax Pharma's Days Payable or its related term are showing as below:
BOM:540359'
s Days Payable Range Over the Past 10 Years
Min: 149.2 Med: 233.36 Max: 453.49
Current: 411.06
During the past 13 years, Parmax Pharma's highest Days Payable was 453.49. The lowest was 149.20. And the median was 233.36.
BOM:540359's Days Payable is ranked better than 93.41% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:540359: 411.06
Parmax Pharma's Days Payable
increased
from Mar. 2025 (251.30) to Mar. 2026 (402.31).
It may suggest that Parmax Pharmadelayed paying its suppliers.
Parmax Pharma Days Payable Related Terms
Parmax Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Parmax Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma (BOM:540359) has a Days Payable of 402.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Parmax Pharma and its competitors. This is 72% above median its historical median of 233.36. Over the past decade, Parmax Pharma's Days Payable has ranged from 149.20 to 453.49. According to the industry distribution chart, Parmax Pharma ranks #61 out of 925 companies in the Drug Manufacturers industry, placing it in the top 6.6%.
Is Parmax Pharma's Days Payable too high?
Parmax Pharma's current Days Payable of 402.31 is 72% above median its 10-year median of 233.36. Over the past 10 years, this metric has ranged from a low of 149.20 to a high of 453.49. The Drug Manufacturers industry median Days Payable is 90.38. Parmax Pharma's value of 402.31 is 345.1% above this industry median. Based on the distribution chart, Parmax Pharma ranks #61 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Parmax Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #61 out of 925 companies for Days Payable. This places Parmax Pharma in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Parmax Pharma's value of 402.31 is 345.1% above this benchmark. Historically, Parmax Pharma's own Days Payable has ranged from 149.20 to 453.49 over the past decade. While the company's 10-year median is 233.36 vs. the industry median of 90.38, Parmax Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parmax Pharma's current Days Payable of 402.31 is 345.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current Days Payable is 402.31, which is 72% above median its own 10-year median of 233.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.56, compared to a current price of ₹102.92 — trading 302.7% above its estimated fair value. The current Days Payable is 402.31, which is 72% above median its 10-year median of 233.36 and 345.1% above the Drug Manufacturers industry median of 90.38. Parmax Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Days Payable is 402.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹102.92 is trading 302.7% above its estimated GF Value™ of ₹25.56.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
Days Payable: 402.31 (72% above median its 10-year median of 233.36)
GF Value™: ₹25.56 vs. price of ₹102.92 (302.7% above fair value)
Industry Position: 345.1% above the Drug Manufacturers median (#61 of 925)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
